Evidence map›Paper›PMID 39969567›Full record

ArticleAnalytical and bioanalytical chemistry2025

Selective determination of 3,5-dihydroxycinnamic acid in urine samples as gluten intake biomarker: high-performance thin-layer chromatography combined with colorimetric detection.

A Martínez-Aviñó, L Sanjuan-Navarro, Yolanda Moliner-Martínez, M Roca, C Ribes-Koninckx, P Campins-Falco

Abstract read
In one paragraph

Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

A Martínez-AviñóMINTOTA Research Group, Departament de Química Analítica, Facultad de Química, Universitat de Valencia, C/Doctor Moliner 50, 46100, Burjassot, Valencia, Spain.
L Sanjuan-NavarroMINTOTA Research Group, Departament de Química Analítica, Facultad de Química, Universitat de Valencia, C/Doctor Moliner 50, 46100, Burjassot, Valencia, Spain.
Yolanda Moliner-MartínezMINTOTA Research Group, Departament de Química Analítica, Facultad de Química, Universitat de Valencia, C/Doctor Moliner 50, 46100, Burjassot, Valencia, Spain. Yolanda.moliner@uv.es.
M RocaCeliac Disease and Digestive Immunopathology Unit, Instituto de Investigación Sanitaria La Fe, 46026, Valencia, Spain.
C Ribes-KoninckxCeliac Disease and Digestive Immunopathology Unit, Instituto de Investigación Sanitaria La Fe, 46026, Valencia, Spain.
P Campins-FalcoMINTOTA Research Group, Departament de Química Analítica, Facultad de Química, Universitat de Valencia, C/Doctor Moliner 50, 46100, Burjassot, Valencia, Spain.

Funding

Generalitat Valenciana ID-FEDER/2018/049Generalitat Valenciana PROMETEO CIPROM/2023/46Instituto de Salud Carlos III (ISCIII) PI20/01269Ministerio de Ciencia, Innovación y Universidades EU FEDER -AEI (PID2021-124554NB-I00)Ministerio de Ciencia, Innovación y Universidades RED2022-134079-T funded by MICIU/AEI/10.13039/5011Universitat de Valencia VLC-BIOMED (AK-GluDETECT)
6 · The paper itself

Abstract

The determination of biomarkers is a significant field of analytical chemistry research under continuous evolution that contributes to enhance diagnostics and enable more personalized medicine. Celiac disease is a systemic autoimmune disorder caused by the ingestion of gluten (Glu) proteins found in various cereals. Currently, the only effective way to prevent and manage potential complications is through a strict gluten-free diet (GFD). However, both intentional and unintentional dietary transgressions can occur, often leading to persistent symptoms and ineffective treatment. In this scenario, the development of analytical strategies to detect biomarkers of gluten intake and monitor adherence to a GFD is of significant interest. Herein, we present an analytical strategy based on high-performance thin-layer chromatography (HPTLC) combined with colorimetric detection to estimate 3,5-dihydroxycinnamic acid (3,5-DHCA) as selective biomarker of Glu intake in urine. The approach combined Fast Blue (FB)-doped polydimethylsiloxane (PDMS) membrane with colorimetric HPTLC (RP-C18) giving rise to a selective method to isolate 3,5-DHCA response in urine samples. Detection by visual inspection, image analysis, and spectroscopic response was evaluated and compared. Analytical parameters were estimated showing a good sensitivity (limit of detection (LOD) ≤ 0.8 mg L

Indexed as

Celiac DiseaseCinnamatesColorimetryGlutensBiomarkersChromatography, Thin LayerDiet, Gluten-FreeHumansLimit of DetectionBiomarkersCinnamatesGlutens3,5-DHCAColorimetric HPTLCGlutenPDMS-based sensorTarget biomarker

Identifiers

PMID39969567
PMCPMC11961461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.